Alnylam Presents 18-Month Results From The APOLLO-B Phase 3 Study Of Patisiran In Patients With ATTR Amyloidosis With Cardiomyopathy
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals announced 18-month results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic for ATTR amyloidosis with cardiomyopathy. The results showed sustained benefits in functional capacity, health status, and quality of life, as well as cardiac stress and injury. The safety profile remained consistent with the 12-month double-blind period, with no new safety findings.
May 20, 2023 | 7:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals' APOLLO-B Phase 3 study of patisiran showed sustained benefits in functional capacity, health status, and quality of life for ATTR amyloidosis with cardiomyopathy patients, with no new safety findings.
The positive 18-month results from the APOLLO-B Phase 3 study of patisiran indicate that the investigational RNAi therapeutic has the potential to provide sustained clinical benefits for patients with ATTR amyloidosis with cardiomyopathy. This could lead to increased interest in Alnylam Pharmaceuticals and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100